Replimune Group (NASDAQ:REPL) Stock Price Down 5.6% - What's Next?

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s share price was down 5.6% on Friday . The stock traded as low as $10.99 and last traded at $10.95. Approximately 384,744 shares changed hands during mid-day trading, a decline of 45% from the average daily volume of 694,876 shares. The stock had previously closed at $11.60.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on REPL. BMO Capital Markets raised their target price on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a report on Wednesday, January 22nd. Jefferies Financial Group boosted their target price on Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday, December 4th. JPMorgan Chase & Co. increased their price target on Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Finally, HC Wainwright boosted their price objective on Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $19.43.

Replimune Group Trading Down 4.7 %

The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $811.28 million, a price-to-earnings ratio of -3.43 and a beta of 1.30. The business has a 50 day simple moving average of $12.66 and a 200-day simple moving average of $12.16.

Remove Ads

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09). On average, equities analysts predict that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in REPL. GSA Capital Partners LLP bought a new position in Replimune Group in the third quarter worth about $222,000. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Replimune Group by 25.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 128,208 shares of the company's stock worth $1,405,000 after purchasing an additional 25,939 shares during the period. Intech Investment Management LLC bought a new stake in shares of Replimune Group in the 3rd quarter worth approximately $252,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Replimune Group by 12.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company's stock worth $5,313,000 after purchasing an additional 52,498 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Replimune Group by 24.9% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 184,208 shares of the company's stock valued at $2,019,000 after purchasing an additional 36,689 shares during the period. 92.53% of the stock is owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.